(Q36792997)

16 August 2017

1 reference

title

The promise of TRAIL--potential and risks of a novel anticancer therapy (English)

1 reference

16 August 2017

Ronald Koschny

1

1 reference

16 August 2017

Henning Walczak

series ordinal

2

1 reference

16 August 2017

Tom M Ganten

series ordinal

3

1 reference

16 August 2017

publication date

17 April 2007

1 reference

Journal of Molecular Medicine

16 August 2017

published in

1 reference

16 August 2017

volume

85

1 reference

16 August 2017

issue

9

1 reference

16 August 2017

page(s)

923-935

1 reference

Hepatitis B virus sensitizes hepatocytes to TRAIL-induced apoptosis through Bax.

16 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00109-007-0194-1

Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00109-007-0194-1

TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00109-007-0194-1

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

21 January 2018

1 reference

12 December 2020

mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells

1 reference

12 December 2020

Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression

1 reference

12 December 2020

New apoptosis drugs face critical test

1 reference

12 December 2020

Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells

1 reference

12 December 2020

Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells

1 reference

12 December 2020

The complementary roles of the extrinsic and intrinsic apoptotic pathways in promoting the death of cancer cells.

1 reference

12 December 2020

The clinical trail of TRAIL.

1 reference

12 December 2020

Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies

1 reference

12 December 2020

Functional analysis of TRAIL receptors using monoclonal antibodies

1 reference

12 December 2020

Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis.

1 reference

12 December 2020

Enhanced apoptosis of soft tissue sarcoma cells with chemotherapy: A potential new approach using TRAIL

1 reference

12 December 2020

Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.

1 reference

12 December 2020

Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes

1 reference

12 December 2020

Low-dose UV-radiation sensitizes keratinocytes to TRAIL-induced apoptosis

1 reference

12 December 2020

An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.

1 reference

12 December 2020

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

1 reference

12 December 2020

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

1 reference

12 December 2020

Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway

1 reference

12 December 2020

Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.

1 reference

12 December 2020

Hepatocytes in collagen sandwich: evidence for transcriptional and translational regulation

1 reference

12 December 2020

TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells

1 reference

12 December 2020

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

1 reference

12 December 2020

Tumor-necrosis-factor-related apoptosis-inducing-ligand (TRAIL)-mediated death of neurons in living human brain tissue is inhibited by flupirtine-maleate

1 reference

12 December 2020

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy

1 reference

12 December 2020

Death receptor-induced cell killing

1 reference

12 December 2020

TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies

1 reference

12 December 2020

1 reference

12 December 2020

Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.

1 reference

12 December 2020

HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma

1 reference

12 December 2020

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

1 reference

12 December 2020

Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells

1 reference

12 December 2020

The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice

1 reference

12 December 2020

TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas.

1 reference

12 December 2020

Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells

1 reference

12 December 2020

Is TRAIL hepatotoxic?

1 reference

12 December 2020

Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function

1 reference

12 December 2020

The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems

1 reference

12 December 2020

Pathways involved in proliferating, senescent and immortalized keratinocyte cell death mediated by two different TRAIL preparations

1 reference

12 December 2020

Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells

1 reference

12 December 2020

Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1.

1 reference

12 December 2020

Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter

1 reference

12 December 2020

Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells

1 reference

12 December 2020

TRAIL and its receptors as targets for cancer therapy

1 reference

12 December 2020

Avoiding premature apoptosis of normal epidermal cells

1 reference

12 December 2020

Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy

1 reference

12 December 2020

Histone deacetylase inhibitors: discovery and development as anticancer agents

1 reference

12 December 2020

Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia.

1 reference

12 December 2020

Tumor necrosis factor related apoptosis inducing ligand triggers apoptosis in dividing but not in differentiating human epidermal keratinocytes.

1 reference

12 December 2020

Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation

1 reference

12 December 2020

Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand

1 reference

12 December 2020

Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells

1 reference

12 December 2020

The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand.

1 reference

12 December 2020

Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1

1 reference

12 December 2020

Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with speci

1 reference

12 December 2020

Eradication of established tumors in mice by a combination antibody-based therapy

1 reference

12 December 2020

TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window.

1 reference

12 December 2020

Upregulation of TRAIL-R2 is not involved in HDACi mediated sensitization to TRAIL-induced apoptosis

1 reference

12 December 2020

High level of cFLIP correlates with resistance to death receptor-induced apoptosis in bladder carcinoma cells

1 reference

12 December 2020

c-FLIPR, a new regulator of death receptor-induced apoptosis.

1 reference

12 December 2020

TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma

1 reference

12 December 2020

HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL.

1 reference

12 December 2020

Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer.

1 reference

12 December 2020

Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma

1 reference

12 December 2020

Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis

1 reference

12 December 2020

Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.

1 reference

12 December 2020

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells

1 reference

12 December 2020

Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells

1 reference

12 December 2020

Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.

1 reference

12 December 2020

Defining characteristics of Types I and II apoptotic cells in response to TRAIL.

1 reference

12 December 2020

Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D.

1 reference

12 December 2020

Targeting death receptors in cancer with Apo2L/TRAIL.

1 reference

12 December 2020

Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake

1 reference

12 December 2020

Blockade of TRAIL pathway ameliorates HBV-induced hepatocyte apoptosis in an acute hepatitis model

1 reference

12 December 2020

Isolation, culture and characterization of adult human hepatocytes from surgical liver biopsies

1 reference

12 December 2020

The inhibitor of apoptosis protein family and its antagonists in acute leukemias

1 reference

12 December 2020

Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.

1 reference

12 December 2020

Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells.

1 reference

12 December 2020

Tumor therapeutics by design: targeting and activation of death receptors

1 reference

12 December 2020

Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2

1 reference

12 December 2020

Safety and antitumor activity of recombinant soluble Apo2 ligand

1 reference

12 December 2020

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

1 reference

12 December 2020

A CD40–CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95

1 reference

12 December 2020

Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4

1 reference

12 December 2020

Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1).

1 reference

12 December 2020

Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety

1 reference

12 December 2020

Involvement of TRAIL and its receptors in viral hepatitis

1 reference

12 December 2020

1 reference

12 December 2020

In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL.

1 reference

12 December 2020

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

12 December 2020

TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infections

1 reference

12 December 2020

Hepatocyte growth factor induces Mcl-1 in primary human hepatocytes and inhibits CD95-mediated apoptosis via Akt.

1 reference

12 December 2020

Identification and characterization of a new member of the TNF family that induces apoptosis

1 reference

12 December 2020

TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.

1 reference

12 December 2020

The interplay between the Bcl-2 family and death receptor-mediated apoptosis

1 reference

12 December 2020

1 reference

12 December 2020

TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors

1 reference

12 December 2020

TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis

1 reference

12 December 2020

TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice

1 reference

12 December 2020

Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells

1 reference

12 December 2020

Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.

1 reference

12 December 2020

Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)

1 reference

12 December 2020

Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies

1 reference

12 December 2020

Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins

1 reference

12 December 2020

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

1 reference

12 December 2020

Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy.

1 reference

12 December 2020

Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer

1 reference

12 December 2020

Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice

1 reference

12 December 2020

Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model

1 reference

12 December 2020

Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.

1 reference

12 December 2020

TRAIL receptor-targeted therapy.

1 reference

12 December 2020

TRAIL and chemotherapeutic drugs in cancer therapy

1 reference

12 December 2020

Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.

1 reference

12 December 2020

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

1 reference

12 December 2020

The essential role of the mitochondria-dependent death-signaling cascade in chemotherapy-induced potentiation of Apo2L/TRAIL cytotoxicity in cultured thoracic cancer cells: amplified caspase 8 is indispensable for combination-mediated massive cell d

1 reference

12 December 2020

Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells

1 reference

12 December 2020

Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer

1 reference

12 December 2020

Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types

1 reference

12 December 2020

Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins

1 reference

12 December 2020

Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice

1 reference

12 December 2020

Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2.

1 reference

12 December 2020

FLIP protein and TRAIL-induced apoptosis

1 reference

12 December 2020

Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells

1 reference

12 December 2020

10.1007/S00109-007-0194-1

Identifiers

DOI

1 reference

16 August 2017

1 reference